CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 376 enrolled
Drug / intervention
ESBA1008 solution +1 morebiological
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01304693
NCT01304693Phase 2Completed
CompareCT.gov

Safety and Efficacy Study of ESBA1008 Versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration

Alcon Research·interventional·Posted Feb 25, 2011·Updated Jul 17, 2014

In Brief

A Phase 2 clinical trial evaluating ESBA1008 solution and Ranibizumab 0.5 mg for Exudative Age-Related Macular Degeneration. Completed, enrolled 376 participants.

Detailed Summary

The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExudative Age-Related Macular Degeneration
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.4 years ago

Interventions

ESBA1008 solutionbiological

Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)

Ranibizumab 0.5 mgbiological

Administered as a single intravitreal injection